Peer-Reviewed Publication
Blood Adv2026;10(11):3945-3959.June 9, 2026Journal Article
Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy.
Sigrun Einarsdottir1, Teng Fei2, Katina Singh3, Michael Martens4,5, Jo-Anne H Young6, Kavita Bhavsar4, Jianqun Kou4, Min Chen4, Lik Wee Lee7, Aliyah Baluch8, Madhav V Dhodapkar9, Ryotaro Nakamura10, Kristin Peyton11, Zainab Shahid12, Paul Armistead13, Peter Westervelt14, John McCarty15, Joseph McGuirk16, Mehdi Hamadani17, Elad Sharon18, Ashley Spahn19, Amir A Toor20, Stephanie Waldvogel19, Lee M Greenberger21, Jeffery J Auletta19,22, Mary M Horowitz4, Marcie L Riches4, Kinga Hosszu3, Joshua A Hill23,24, Susan DeWolf1,25, Miguel-Angel Perales1,25
1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
2Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY.
3Department of Pediatrics, Immune Discovery and Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY.
4Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin, Milwaukee, WI.
5Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI.
6Department of Medicine, Division of Infectious Disease and International Medicine, Program in Adult Transplant Infectious Disease, University of Minnesota, Minneapolis, MN.
7Adaptive Biotechnologies Corp, Seattle, WA.
8Division of Infectious Diseases, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
9Department of Hematology and Medical Oncology, School of Medicine, Emory University, Atlanta, GA.
10Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
11The Emmes Company, Rockville, MD.
12Department of Infectious Diseases, Memorial Sloan Kettering Cancer Center, New York, NY.
13Division of Hematology, University of North Carolina Medical Center, Chapel Hill, NC.
14Division of Oncology, Barnes-Jewish Hospital, Washington University, St. Louis, MO.
15Massey Comprehensive Cancer Center, Richmond, VA.
16Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas, Lawrence, KS.
17Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
18National Cancer Institute, Bethesda, MD.
19Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, MN.
20Department of Medicine, University of Texas Southwestern, Dallas, TX.
21Blood Cancer United, Washington, DC.
22Division of Hematology/Oncology/BMT and Infectious Diseases, Nationwide Children's Hospital, Columbus, OH.
23Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.
24Department of Medicine, University of Washington, Seattle, WA.
25Department of Medicine, Weill Cornell Medical College, New York, NY.
Abstract
The optimal timing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination after cellular therapies remains uncertain. In a previous prospective multicenter cohort (n = 466), we found no differences in humoral or SARS-CoV-2-specific T-cell receptor (TCR) responses between patients vaccinated early (<4 months) vs later (4-12 months) after allogeneic hematopoietic cell transplant…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans